US Patent

US12245996 — Norepinephrine compositions and methods therefor

Formulation · Assigned to Nevakar Injectables Inc · Expires 2038-01-30 · 12y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions and methods for ready-to-inject norepinephrine with improved stability, preferably free of antioxidants and with minimal isomerization and degradation.

USPTO Abstract

The inventive subject matter is directed to compositions and methods for ready-to-inject norepinephrine compositions with improved stability. Most preferably, compositions presented herein are substantially antioxidant free and exhibit less than 10% isomerization of R-norepinephrine and exhibit less than 5% degradation of total norepinephrine.

Drugs covered by this patent

Patent Metadata

Patent number
US12245996
Jurisdiction
US
Classification
Formulation
Expires
2038-01-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Nevakar Injectables Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.